Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study.
Inal A, Kos FT, Algin E, Yildiz R, Berk V, Tugba Unek I, Colak D, Colak D, Kucukoner M, Tamer Elkiran E, Helvaci K, Geredeli C, Dane F, Balakan O, Ali Kaplan M, Gok Durnali A, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Ozkan M, Benekli M, Isikdogan A; Anatolian Society Of Medical Oncology. Inal A, et al. Among authors: kos ft. J BUON. 2012 Jan-Mar;17(1):102-5. J BUON. 2012. PMID: 22517701
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Inal A, Kos FT, Algin E, Yildiz R, Dikiltas M, Unek IT, Colak D, Elkiran ET, Helvaci K, Geredeli C, Dane F, Balakan O, Kaplan MA, Durnali AG, Harputoglu H, Goksel G, Ozdemir N, Buyukberber S, Gumus M, Kucukoner M, Ozkan M, Uncu D, Benekli M, Isikdogan A. Inal A, et al. Among authors: kos ft. Neoplasma. 2012;59(3):297-301. doi: 10.4149/neo_2012_038. Neoplasma. 2012. PMID: 22329849
Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).
İnal A, Kos FT, Algın E, Yıldız R, Berk V, Unek İT, Colak D, Dane F, Geredeli C, Isıkdogan A. İnal A, et al. Among authors: kos ft. Contemp Oncol (Pozn). 2015;19(2):125-9. doi: 10.5114/wo.2014.43933. Epub 2015 May 13. Contemp Oncol (Pozn). 2015. PMID: 26034390 Free PMC article.
Bevacizumab versus aflibercept with FOLFIRI after FOLFOX and bevacizumab in RAS mutant metastatic colon cancer a Turkish oncology group study.
Sekmek S, Ozsan Çelebi SN, Bayram D, Erol C, Kos FT, Sendur MAN, Altıntas YE, Tuylu T, Yildirim S, Biter S, Kıdı MM, Bayram E, Majidova N, Bayoglu IV, Atak M, Baskurt K, Akbas S, Alkan A, Bayramgil A, Aslan F, Sahin E, Balcik OY, Bayhan AZ, Saray S, Arpaci E, Ergun Y. Sekmek S, et al. Among authors: kos ft. Sci Rep. 2024 Nov 30;14(1):29785. doi: 10.1038/s41598-024-81371-5. Sci Rep. 2024. PMID: 39616250 Free PMC article.
Clinical features and prognostic factors in thymoma and thymic carcinoma.
Bayram D, Sekmek S, Kayaalp M, Bardakçı M, Hafızoğlu E, Uçar G, Algin E, Bal O, Civelek B, Şendur MAN, Kos FT, Uncu D. Bayram D, et al. Among authors: kos ft. Indian J Thorac Cardiovasc Surg. 2024 Nov;40(6):660-668. doi: 10.1007/s12055-024-01741-6. Epub 2024 May 14. Indian J Thorac Cardiovasc Surg. 2024. PMID: 39416339
The HALP score as a prognostic factor in metastatic biliary cancer.
Seven İ, Karahan İ, Köş FT, Bayram D, Sekmek S, Aktürk Esen S. Seven İ, et al. Among authors: kos ft. Clin Transl Oncol. 2024 Sep 13. doi: 10.1007/s12094-024-03702-2. Online ahead of print. Clin Transl Oncol. 2024. PMID: 39271621
32 results